Financial Performance - Q1 2025 net sales reached $1.2 billion, aligning with the midpoint of the company's guidance range[12] - Net sales increased by 1.4% year-over-year on a constant currency basis[12] - Adjusted EBITDA for Q1 2025 was $165 million, exceeding the company's guidance[12] - Adjusted EBITDA at constant currency was $182 million, also exceeding guidance[12] - The company reduced its total leverage ratio to 3.0x by March 31[12] Growth & Expansion - New distributors increased by 16% year-over-year worldwide, marking the fourth consecutive quarter of improvement[12] - The company completed acquisitions of certain assets of Pro2col Health LLC, Pruvit Ventures, Inc, and formed a 51% ownership interest in HBL Link Bioscience LLC[12] Strategic Initiatives - The company announced the all-new Herbalife Flex45 Challenge[12] - The company expanded the global rollout of the Diamond Development Mastermind Program to China[12] Financial Outlook - The company anticipates net sales to decrease between 3.5% to increase 0.5% year-over-year for Q2 2025, with adjusted EBITDA between $160 million and $170 million[38] - On a constant currency basis, the company expects net sales to decrease between 0.5% to increase 3.5% year-over-year for Q2 2025, with adjusted EBITDA between $177 million and $187 million[38]